The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

The US Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC ...

Adding atezolizumab and bevacizumab to TACE can improve outcomes in previously untreated, unresectable HCC, data suggest.